Emmaus Life Sciences Announces Endari To Be Added to the Florida Medicaid Preferred Drug ListMarch 29, 2022
Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients
Read More
Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients
Read MoreEmmaus Life Sciences, Inc. today announced the approval of its application for marketing authorization of Endari® from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company’s marketing authorization application.
Read MoreEmmaus Life Sciences, Inc. today announced that real world data on Endari®, the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology (BSH) to be held April 3 -5, 2022 at the Manchester Central in Manchester, England and virtually.
Read MoreEmmaus Life Sciences, Inc. today announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2022
Read MoreAnalysis Indicates that Patients Requiring Blood Transfusions and Receiving Endari Required ~43% Fewer Units of Red Blood Cells
Read More